Trials / Completed
CompletedNCT01681290
Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta™), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects With Mild to Moderate Diabetic Peripheral Neuropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 250 (actual)
- Sponsor
- Cebix Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the beneficial effects of CBX129801 (PEGylated synthetic human C-peptide) following weekly subcutaneous administration for 12 months in type 1 diabetes mellitus patients (T1DM) with mild to moderate diabetic peripheral neuropathy (DPN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CBX129801 |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2014-11-01
- Completion
- 2015-01-01
- First posted
- 2012-09-07
- Last updated
- 2015-01-30
Locations
29 sites across 3 countries: United States, Canada, Sweden
Source: ClinicalTrials.gov record NCT01681290. Inclusion in this directory is not an endorsement.